This could also address Daiichi Sankyo’s denial of the compliance issues.
The Sun Ranbaxy acquisition:
With a reputation that precedes him, Dilip Shanghvi, the Managing Director of Sun Pharmaceuticals, has had enough experience with acquiring failing companies and turning its fortunes. Ranbaxy Laboratories, was Sun’s 18th acquisition since 1996, and there was and still is consensus in the Pharmaceutical Industry that this move is in the best interests of all the players involved.
Shanghvi, who has led the company from the front, brings the type of decisive leadership Ranbaxy had lacked under Daiichi Sankyo. Without a strong leadership and direction, Ranbaxy had floundered and cost Daiichi dearly, eventually leading to its sale. Irrespective of how it was put across, this was a distress sale. Ranbaxy had been acquired by Daiichi Sankyo as a key part in their overseas strategy and was to serve as its foot into the generic drug market. But after six long, painful years and burning away around $5 billion, Ranbaxy was sold to Sun Pharma at a discount 38% of its acquisition price in 2008.
Why did SUN acquire Ranbaxy? Why might SUN succeed where Daiichi